GT Biopharma, Inc. (GTBP) Income Statement
GTBP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGTBP revenue and net income
GTBP profit margins
GTBP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GTBP quarterly EPS vs estimates
GT Biopharma beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 13, 2026 (estimate $-2.50).
GTBP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $27,000 | $0 |
| Cost of revenue | — | — | — | — | — | — | $4,000 | $7,000 | $2,000 | $1,000 |
| Gross profit | — | — | — | — | — | — | −$4,000 | −$7,000 | −$2,000 | −$1,000 |
| Research & development | $3.5M | $5.8M | $6.5M | $8.8M | $9.6M | $485,000 | $1.7M | $9.1M | $1.1M | $975,000 |
| Sales, general & admin | $8.9M | $8.6M | $8.2M | $12.4M | $47.9M | $6.3M | $9.8M | $12.5M | $134.5M | $8.4M |
| Total operating expenses | $12.4M | $14.4M | $13.6M | $21.3M | $57.5M | $6.8M | $11.5M | $21.6M | $135.6M | $9.4M |
| Operating income | −$12.4M | −$14.4M | −$13.6M | −$21.3M | −$57.5M | −$6.8M | −$11.5M | −$250.1M | −$135.6M | −$9.4M |
| Interest income | $123,000 | $402,000 | $741,000 | $292,000 | $38,000 | $0 | — | — | — | — |
| Interest expense | $127,000 | $0 | $213,000 | $8,000 | $718,000 | $3.3M | $2.1M | $9.1M | $8.6M | $6.6M |
| Income before taxes | −$28.4M | −$13.2M | −$7.6M | −$20.9M | −$58.0M | −$28.3M | −$38.6M | −$259.2M | −$144.2M | $9.8M |
| Income taxes | — | — | −$13,576 | −$381,000 | $680,000 | $3.3M | $2.1M | −$228.5M | $7.7M | −$30.4M |
| Net income | −$28.4M | −$13.2M | −$7.6M | −$20.9M | −$58.0M | −$28.3M | −$38.6M | −$259.2M | −$144.2M | $9.8M |
| EBITDA | −$28.2M | −$13.2M | $6.0M | −$21.0M | −$57.5M | −$25.0M | −$36.5M | −$250.1M | −$135.6M | −$9.4M |
| EPS (diluted) | −$123.14 | −$7.00 | −$9.71 | −$9.82 | −$80.27 | −$3.57 | −$0.67 | −$5.16 | −$234.22 | −$499.27 |
| Gross margin | — | — | — | — | — | — | — | — | −7.4% | — |
| Operating margin | — | — | — | — | — | — | — | — | −502,111.1% | — |
| Net margin | — | — | — | — | — | — | — | — | −533,970.4% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.1M | $413,000 | $1.4M | $634,000 | $363,000 | $1.1M | $1.9M | $1.3M | $1.8M | $777,000 | $1.4M | $1.4M |
| Sales, general & admin | $3.4M | $2.4M | $4.2M | $2.7M | $1.1M | $833,000 | $2.1M | $2.3M | $2.1M | $2.3M | $1.8M | $1.8M |
| Total operating expenses | $4.5M | $2.8M | $5.6M | $3.4M | $1.5M | $1.9M | $3.8M | $3.6M | $3.9M | $3.1M | $3.2M | $3.1M |
| Operating income | −$4.5M | −$2.8M | −$5.6M | −$3.4M | −$1.5M | −$1.9M | −$3.8M | −$3.6M | −$3.9M | −$3.1M | −$3.2M | −$3.1M |
| Interest income | — | $67,000 | $17,000 | $36,000 | $38,000 | $32,000 | $59,000 | $96,000 | $105,000 | $142,000 | $180,000 | $216,000 |
| Interest expense | $64,000 | $63,000 | $127,000 | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$4.5M | −$2.8M | −$23.0M | $8.3M | −$30.2M | −$776,000 | −$3.8M | −$3.4M | −$3.7M | −$2.3M | −$3.0M | −$2.4M |
| Income taxes | — | — | — | — | — | $3.1M | $3.1M | — | −$3.9M | −$3.1M | −$3,168 | −$3,122 |
| Net income | −$4.5M | −$2.8M | −$23.0M | $8.3M | −$30.2M | −$776,000 | −$3.8M | −$3.4M | −$3.7M | −$2.3M | −$3.0M | −$2.4M |
| EBITDA | −$4.5M | −$2.8M | −$21.4M | $8.3M | −$30.2M | −$776,000 | −$3.8M | −$3.4M | −$3.7M | $825,000 | −$3.0M | −$2.4M |
| EPS (diluted) | −$0.12 | −$0.11 | −$121.00 | −$0.83 | −$0.55 | −$0.76 | −$1.66 | −$1.53 | −$2.17 | −$1.64 | −$2.19 | −$2.13 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GTBP's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GTBP financial results
GT Biopharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $28.4 million. Diluted earnings per share came to −$123.14.
See the GTBP stock overview for the latest quote and news, or the GTBP chart for price history and technical indicators.
GTBP income statement FAQ
Does GT Biopharma have revenue?
GT Biopharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is GT Biopharma profitable?
No. GT Biopharma reported a net loss of $28.4 million in fiscal 2025.
How much does GT Biopharma spend on research and development?
GT Biopharma spent $3.5 million on research and development in fiscal 2025.
What are GT Biopharma's earnings per share?
GT Biopharma earned $-123.14 per diluted share in fiscal 2025, compared with $-7.00 a year earlier.
When will GT Biopharma report its next earnings?
GT Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does GT Biopharma's fiscal year end?
GT Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.